Key distinctions include: GLP-1 therapies primarily reduce appetite support blood sugar regulation encourage gradual weight loss Retatrutide reduces appetite improves insulin sensitivity increases metabolic rate promotes fat oxidation may support lean muscle preservation This broader metabolic influence is why researchers believe triple-agonist peptides may represent the next evolution of medical weight management therapies
Acknowledgements Illustrations were created with Biorender
Fatigue is a recognised adverse reaction in the product information for some GLP-1 medications, particularly those used at higher doses for weight management (such as semaglutide 2.4 mg and liraglutide 3 mg)
However, for a more sustained and significant improvement in chronic fatigue, it often takes several weeks or even a couple of months of regular injections for the body to fully restore its B12 stores and for symptoms to noticeably subside
Brand tirzepatide keeps until its printed expiration date when stored at 3646F (28C)
For example, semaglutide dosing often builds up to 2.4 mg per week, while tirzepatide can go as high as 15 mg